Mutations in the amyotrophic lateral sclerosis 2 (juvenile) (*ALS2*) gene (Online Mendelian Inheritance in Man \*606352) cause autosomal recessive motor neuron diseases, including juvenile-onset amyotrophic lateral sclerosis (JALS),^[@R1]^ juvenile-onset primary lateral sclerosis, and infantile-onset ascending hereditary spastic paraplegia.^[@R2],[@R3]^ In JALS, both upper and lower motor neurons are affected, whereas neurodegeneration involves only upper motor neurons in juvenile-onset primary lateral sclerosis and infantile-onset ascending hereditary spastic paraplegia. Despite these differences in neuropathology, almost all mutations in *ALS2* described to date result in a clinical phenotype of infantile onset of limb and facial muscle weakness, accompanied by bulbar symptoms, which generally progresses to paraplegia during childhood. Rarely, patients with JALS have been reported with lower motor neuron involvement.^[@R4]^ *ALS2* mutations are distributed widely across the entire coding sequence and mostly result in loss of protein function.^[@R4][@R5][@R6]^

Using exome sequencing and a candidate gene sequencing approach, we identified mutations in *ALS2* in 2 consanguineous families with a novel phenotype of generalized dystonia and a spastic quadriparesis.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

Study approval was given by each local ethics committee, and both families gave informed consent.

Subjects. {#s1-2}
---------

Pedigrees for the families are presented in the [figure](#F1){ref-type="fig"}. The clinical characteristics of the patients are described in the results section.

![Pedigree for family 1 (A) and family 2 (B)\
An arrow indicates the proband in each family.](NEUROLOGY2013554238FF1){#F1}

Genetic methodology. {#s1-3}
--------------------

### Family 1. {#s1-3-1}

Homozygosity mapping (in II:1--II:3) and exome sequencing (in II:2) was performed ([figure, A](#F1){ref-type="fig"}). Only variants within regions of homozygosity, shared only by the affected siblings, were used for filtering. We filtered out synonymous variants and any variant present in a range of publicly available databases of sequence variation (dbSNP, 1000 Genomes, Complete Genomic 69 Database, and National Heart, Lung, and Blood Institute \[NHLBI\] Exome Sequencing Project database).

### Family 2. {#s1-3-2}

A candidate gene sequencing approach was used in this family for the following genes: *SPG11*, *Spastizin*, and *ALS2* ([figure, B](#F1){ref-type="fig"}). All coding exons and flanking intronic sequences were amplified by touchdown PCR and Sanger sequenced.

RESULTS {#s2}
=======

Clinical features. {#s2-1}
------------------

### Family 1. {#s2-1-1}

The index case ([figure, A](#F1){ref-type="fig"} \[II:2\]) is of Bangladeshi descent. Early motor milestones were normal; however, she failed to walk independently, prompting assessment at age 2 years. Assessment at this time revealed a mild spastic diplegia with global developmental delay and microcephaly (below 2nd percentile). She presented to our center at age 13 years; her examination revealed a few beats of nystagmus, a facetious smile, and anarthria. There was marked spasticity and contractures in the limbs with dystonic posturing of the hands. Global muscle weakness was present with distal lower limb wasting suggesting lower motor neuron involvement. She required a motorized wheelchair. Subsequently, surgical intervention was required for a rapidly progressive scoliosis. A trial of [l]{.smallcaps}-dopa was not helpful.

Individual II:3 achieved normal motor milestones up until 12 months of age when he started toe-walking. Examination at age 7 years revealed microcephaly (2nd to 9th percentile), nystagmoid jerks, and intermittent head titubation. In the upper and lower limbs, there was spasticity with clonus and dystonic posturing of the arms and trunk. Gait examination showed truncal sway, suggestive of ataxia. Neck flexors were weak as were proximal and distal muscle groups. Reflexes were pathologically brisk with bilateral extensor plantars. There was a mild scoliosis.

Brain MRI in patient II:2 showed mild lack of white matter bulk and some immaturity of the white matter signal. CSF and an extensive metabolic screen were normal. A muscle biopsy showed angular atrophic fibers with grouping of fast and slow fibers in keeping with a neurogenic component.

### Family 2. {#s2-1-2}

The index case ([figure, B](#F1){ref-type="fig"} \[IV:1\]), a 32-year-old man of Turkish descent (with a similarly affected sister, IV:2), has a complicated dystonia syndrome. Birth and early milestones were normal: he crawled at the age of 8 months and sat at the age of 9 months. Symptom onset was at approximately age 2 to 3 years when he developed an increased tone and difficulty walking. He required a wheelchair from age 8. Speech impairment was observed at age 4 years, which progressed to anarthria at age 15. When he first presented to our hospital at age 18 years, he had a combination of profound weakness, spasticity, and generalized dystonia with dystonic grimacing, intermittent retrocollis, and severe opisthotonus. He is of small stature. Neuraxis MRI, electrophysiology (nerve conduction studies, somatosensory evoked potentials, and blink reflex), and neuropsychological testing were normal at age 18. The patient underwent deep brain stimulation surgery at age 25 years with an unsatisfactory response and further progressive decline. Presently, he is in a cachectic state and lives in a home. He is anarthric and communicates with his eyes. Cognitive function appears relatively intact. Vision is normal. He has dysphagia requiring a percutaneous endoscopic gastrostomy and is incontinent of urine. He has profound muscle atrophy with severe weakness and contractures in both upper and lower limbs. He is on baclofen, tizanidine, and tetrazepam, and receives focal botulinum toxin injections.

See videos 1 and 2 on the *Neurology*® Web site at [Neurology.org](http://Neurology.org), which show affected individuals from families 1 and 2.

Genetic results. {#s2-2}
----------------

### Family 1. {#s2-2-1}

After exome variant filtering, one novel homozygous variant remained, c.G2002T: p.G668X in *ALS2* (ENST00000264276). Sanger sequencing revealed that both affected siblings (II:2 and II:3) are homozygous for the mutation. Their parents (I:1 and I:2) are heterozygous carriers and the unaffected sibling (II:1) does not carry the mutation.

### Family 2. {#s2-2-2}

Sanger sequencing of *SPG11* and *Spastizin* did not reveal any pathogenic mutations. A homozygous frameshift mutation, c.4573dupG; p.V1525fs (ENST00000264276), was identified in the *ALS2* gene in both IV:1 and IV:2, but was not present in the unaffected siblings. The parents were confirmed to be heterozygous carriers of the mutation. Three stop-gain, 1 frameshift, and no splicing *ALS2* variants are recorded in the NHLBI Exome Variant Server in approximately 11,840 alleles. The *ALS2* mutations in family 1 and 2 are absent from this database.

DISCUSSION {#s3}
==========

The differential diagnosis of autosomal recessive dystonia-spasticity syndromes is wide. Tyrosine hydroxylase deficiency may be complicated by additional signs, such as ptosis or oculogyric crises, and is important to exclude as a differential because early treatment with [l]{.smallcaps}-dopa can influence outcome. Patients with *parkin* mutations can present with foot dystonia, parkinsonism, and brisk reflexes. *FBXO7* mutations are associated with a parkinsonian-pyramidal phenotype sometimes accompanied by dystonia. Several of the autosomal recessive spastic paraparesis syndromes can be complicated by dystonia, among other signs (e.g., thinning of the corpus callosum occurs in *SPG11* while retinal degeneration and mental retardation can occur in *SPG15*). Finally, several neurometabolic conditions can present with a young-onset dystonia-spasticity-ataxia syndrome (e.g., GM1 gangliosidosis, Kufs disease type B, and Niemann-Pick disease type C). The prioritization of genetic testing in patients is guided by the presence or absence of additional signs.

We report generalized dystonia, poorly responsive to deep brain stimulation, in association with *ALS2*-related disease. Other novel clinical findings in family 1 include microcephaly and cerebellar signs. It is not clear whether microcephaly or cerebellar signs are a result of the *ALS2* mutation. Additional detailed clinical descriptions of patients with *ALS2* mutations will help to clarify this. In a wild-type mice model of the disease, *ALS2* was highly expressed in the granular and Purkinje layers of the cerebellum, and *ALS2*-null mice have been found to develop an age-dependent slowly progressive loss of cerebellar Purkinje cells.^[@R7]^ The *ALS2* protein binds to a small guanosine triphosphatase RAB5 and functions as a guanine nucleotide exchange factor for RAB5 and has a role in intracellular endosomal trafficking,^[@R7]^ highlighting that this may be an important biological pathway or mechanism through which dystonia may occur.

This report adds to the growing literature widening the phenotypic spectrum of genetic disorders using next-generation sequencing. We propose that the *ALS2* gene should be screened for mutations in patients who present with a similar phenotype.

Supplementary Material
======================

###### Videos
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